[8-K] Microbot Medical Inc. Reports Material Event

Rhea-AI Filing Summary

Microbot Medical announced a partnership with a U.S.-based third-party logistics provider to support commercialization of its FDA-cleared LIBERTY Endovascular Robotic System. The company plans a limited market release in the fourth quarter of 2025, followed by a broader launch in April 2026 aligned with the Society of Interventional Radiology conference.

The disclosure was furnished under Regulation FD and as an Other Event, with a related press release included as Exhibit 99.1.

Insights

Medtech commercialization analyst

Logistics partnership sets timeline for staged LIBERTY rollout.

Microbot Medical is preparing for market entry by engaging a U.S.-based 3PL to handle distribution and commercialization support for its FDA-cleared LIBERTY system. This step addresses supply chain execution and readiness ahead of launch activities.

The company outlines a phased approach: limited market release in Q4 2025 and a broader launch in April 2026 at the Society of Interventional Radiology conference. Exact volumes, sites, and commercial terms are not detailed in the excerpt, so the operational scale will depend on subsequent execution.

Key upcoming milestones are the limited release in Q4 2025 and the broader launch in April 2026. Subsequent filings may provide specifics on distribution scope and adoption metrics.

false 0000883975 0000883975 2025-10-14 2025-10-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 14, 2025

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware		000-19871		94-3078125
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

175 Derby St., Bld. 27

Hingham, MA 02043

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		MBOT		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On October 14 2025, Microbot Medical Inc. (the “Company”) issued a press release announcing that it has partnered with a U.S. based third-party logistics company to support the commercialization of its FDA-cleared LIBERTY^® Endovascular Robotic System.

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

Item 8.01 Other Events.

The Company partnered with a U.S. based third-party logistics (3PL) company to support the commercialization of its FDA-cleared LIBERTY^® Endovascular Robotic System. The Company is expected to initiate the limited market release of the LIBERTY^® System during the fourth quarter of 2025 with the broader launch anticipated to occur in April 2026 during the Society of Interventional Radiology conference.

Forward Looking Statements

This Item 8.01 of this Current Report on Form 8-K may contain “forward-looking statements.” Such statements which are not purely historical (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “intends,” “would,” “could” and “estimates”) are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, regulatory milestones.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company’s reports and statements filed from time-to-time with the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MICROBOT MEDICAL INC.
	By:	/s/ Harel Gadot
	Name:	Harel Gadot
	Title:	Chief Executive Officer, President and Chairman

Date: October 14 2025

FAQ

What did Microbot Medical (MBOT) announce?

The company partnered with a U.S.-based third-party logistics (3PL) firm to support commercialization of its FDA-cleared LIBERTY Endovascular Robotic System.

When will Microbot (MBOT) begin the LIBERTY system rollout?

A limited market release is expected in the fourth quarter of 2025, with a broader launch anticipated in April 2026.

What event is tied to the broader launch of LIBERTY?

The broader launch is anticipated to occur in April 2026 during the Society of Interventional Radiology conference.

Was the information furnished or filed?

The information in Item 7.01 and Exhibit 99.1 was furnished and is not deemed filed under Section 18 of the Exchange Act.

Which exhibit accompanied the announcement?

Exhibit 99.1 contains the press release related to the 3PL partnership and commercialization plans.